IL297363A - Compositions and methods for treatment of acute respiratory distress syndrome - Google Patents

Compositions and methods for treatment of acute respiratory distress syndrome

Info

Publication number
IL297363A
IL297363A IL297363A IL29736322A IL297363A IL 297363 A IL297363 A IL 297363A IL 297363 A IL297363 A IL 297363A IL 29736322 A IL29736322 A IL 29736322A IL 297363 A IL297363 A IL 297363A
Authority
IL
Israel
Prior art keywords
seq
acid sequence
amino acid
antibody
region
Prior art date
Application number
IL297363A
Other languages
English (en)
Hebrew (he)
Original Assignee
Edesa Biotech Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edesa Biotech Res Inc filed Critical Edesa Biotech Res Inc
Publication of IL297363A publication Critical patent/IL297363A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL297363A 2020-04-20 2021-04-20 Compositions and methods for treatment of acute respiratory distress syndrome IL297363A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063012786P 2020-04-20 2020-04-20
US202063012783P 2020-04-20 2020-04-20
US202063081662P 2020-09-22 2020-09-22
PCT/CA2021/050544 WO2021212222A1 (en) 2020-04-20 2021-04-20 Compositions and methods for treatment of acute respiratory distress syndrome

Publications (1)

Publication Number Publication Date
IL297363A true IL297363A (en) 2022-12-01

Family

ID=78270861

Family Applications (1)

Application Number Title Priority Date Filing Date
IL297363A IL297363A (en) 2020-04-20 2021-04-20 Compositions and methods for treatment of acute respiratory distress syndrome

Country Status (8)

Country Link
US (1) US20230192881A1 (https=)
EP (1) EP4138912A4 (https=)
JP (1) JP2023523096A (https=)
CN (1) CN115697410A (https=)
AU (1) AU2021261060A1 (https=)
CA (1) CA3174429A1 (https=)
IL (1) IL297363A (https=)
WO (1) WO2021212222A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020149518A1 (ko) * 2019-01-14 2020-07-23 주식회사 에이아이인사이트 안저영상 자동판독을 위한 딥러닝 아키텍처 시스템 및 딥러닝 아키텍쳐 시스템을 이용한 안저영상 자동판독 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
JP2010526868A (ja) * 2007-05-14 2010-08-05 ノビミューン エスアー 改変されたエフェクター機能を有するＦｃ受容体結合ポリペプチド
US8734790B2 (en) * 2011-01-10 2014-05-27 Novimmune Sa Anti-TLR4 antibodies and methods of use thereof
HUE037613T2 (hu) * 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása
WO2015059168A1 (en) * 2013-10-22 2015-04-30 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
US20170038381A1 (en) * 2015-08-06 2017-02-09 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
CA3037961A1 (en) * 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody

Also Published As

Publication number Publication date
JP2023523096A (ja) 2023-06-01
EP4138912A4 (en) 2024-08-07
CA3174429A1 (en) 2021-10-28
WO2021212222A1 (en) 2021-10-28
CN115697410A (zh) 2023-02-03
EP4138912A1 (en) 2023-03-01
AU2021261060A1 (en) 2022-11-17
US20230192881A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
JP2026016421A (ja) 炎症性状態の処置方法
DK1734997T3 (en) Natalizumab for use in the treatment of diseases requiring steroid treatment
EP3406633A1 (en) Multispecific antibodies, multispecific activatable antibodies and methods of using the same
JP7256741B2 (ja) 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性
JP2019513751A (ja) Ａｎｇｐｔｌ８阻害剤およびａｎｇｐｔｌ３阻害剤を用いて高脂血症を処置するための方法
CN102046199A (zh) 使用抗mif抗体的治疗方法
IL297977A (en) sars-cov-2 antibodies and methods for selecting and using them
AU2020230333A1 (en) Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
KR20200143718A (ko) 이식편 거부반응 예방에 사용하기 위한 항-cd40 항체
JP2017510627A (ja) 多発性硬化症の併用治療
IL302592A (en) Anti-tigit antibodies and uses thereof
JP2023533030A (ja) 小児患者において発作性夜間血色素尿症（ｐｎｈ）を治療するための抗ｃ５抗体の投薬量及び投与
IL298825A (en) ANTI-CTLA-4 binding proteins and methods of using them
US12286469B2 (en) Humanized antibodies binding to amyloid-beta (A-beta)
US10689441B2 (en) Anti—TLR4 antibodies and methods of use thereof
IL321947A (en) Anti-IL-11R antibodies – for the treatment of thyroid-related eye disease
IL297363A (en) Compositions and methods for treatment of acute respiratory distress syndrome
JP2020517605A (ja) 腎臓移植の感作されたレシピエントにおける抗体媒介性拒絶の予防における抗ｃ５抗体の有効性
JP2023539047A (ja) 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与
IL296043A (en) Anti-gitro antibodies and their uses
EP3574020B1 (en) Antibodies to amyloid beta
JP2022169737A (ja) 抗ｒａｍｐ２抗体
US20250289877A1 (en) Antibodies to Amyloid Beta
US11964005B2 (en) Methods of treating atopic dermatitis
US20240287160A1 (en) Antibody cocktail for treatment of ebolavirus infections